Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Recursion official investor newsroom · 行業原文收錄 · 來源發佈:Wed Nov 18 2026 09:59:32 GMT+0000 (Coordinated Universal Time) · 本站收錄:Wed Nov 18 2026 10:08:16 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis November 18, 2026 at 4:59 AM EST PDF Version REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through
以上為帶出處的原文節選,完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。